The Association between Immediate Postpartum Depot Medroxyprogesterone Acetate Use and Postpartum Depressive Symptoms

Abstract

Objective While postpartum depot medroxyprogesterone acetate (DMPA) is a highly effective form of contraception, some data suggest an association with depressive symptoms. Our objective was to evaluate the relationship between receipt of DMPA in the immediate postpartum period and postpartum depressive symptoms.

Study Design This retrospective cohort study included all women who received prenatal and postpartum care at academic obstetric clinics affiliated with a tertiary care institution between January 1, 2008 and December 31, 2014. All women were counseled on contraception prior to hospital discharge. DMPA was available in the hospital pharmacy, and its utilization was documented in the electronic health record. The Patient Health Questionnaire 9 (PHQ-9) was used to screen for postpartum depression for all women at all postpartum visits. A score of 10 or greater was categorized as positive. Bivariable and multivariable analyses were used to identify the association between immediate postpartum DMPA use and a positive postpartum depression screen.

Results Of the 5,073 women who met inclusion criteria, 410 (8.1%) received DMPA prior to hospital discharge. Compared with women who did not receive DMPA, women who received DMPA prior to hospital discharge were younger, more likely to identify as Black race or Latinx ethnicity, and more likely to be publicly insured. Clinical characteristics also differed. Women who received DMPA were more likely to be obese and to have experienced prenatal depressive symptoms, been diagnosed with a hypertensive disorder of pregnancy, delivered preterm, and delivered vaginally. Receipt of immediate postpartum DMPA was not associated with having a positive screen for postpartum depression in bivariable (5.4 vs. 6.0%, p = 0.29) or multivariable (adjusted odds ratio 0.94, confidence interval 0.53–1.68) analyses.

Conclusion Receipt of postpartum DMPA is not associated with a positive postpartum PHQ-9 screen. Concerns about precipitating postpartum depression should not preclude the utilization of DMPA as a contraceptive agent.

Key Points

• Contraception is an important issue for obstetricians to address with postpartum patients.

• Concerns have been raised over the relationship between DMPA and depression.

• Our study shows that DMPA is not associated with a positive postpartum depression screen.

Keywords

postpartum depression - depot medroxyprogesterone acetate (DMPA) - progestin - contraception - PHQ-9

Publikationsverlauf

Eingereicht: 04. August 2020

Angenommen: 04. Oktober 2021

Artikel online veröffentlicht:
14. November 2021

• References

• 1 Schummers L, Hutcheon JA, Hernandez-Diaz S. et al. Association of short interpregnancy interval with pregnancy outcomes according to maternal age. JAMA Intern Med 2018; 178 (12) 1661-1670
• 2 Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep 2011; 60 (26) 878-883
• 3 Holden EC, Lai E, Morelli SS. et al. Ongoing barriers to immediate postpartum long-acting reversible contraception: a physician survey. Contracept Reprod Med 2018; 3 (01) 23
• 4 The Upjohn Company. NDA 20-246. Application summary. Clinical data summary; 1992
• 5 Westhoff C, Truman C, Kalmuss D. et al. Depressive symptoms and depo-provera. Contraception 1998; 57 (04) 237-240
• 6 Westhoff C, Truman C, Kalmuss D. et al. Depressive symptoms and Norplant contraceptive implants. Contraception 1998; 57 (04) 241-245
• 7 Civic D, Scholes D, Ichikawa L. et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception 2000; 61 (06) 385-390
• 8 Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiatry 2016; 73 (11) 1154-1162
• 9 Westhoff C, Wieland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception 1995; 51 (06) 351-354
• 10 Gaynes BN, Gavin N, Meltzer-Brody S. et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 2005; (119) 1-8
• 11 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16 (09) 606-613
• 12 McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. Contraception for women with psychiatric disorders. Am J Psychiatry 2021; 178 (03) 247-255
• 13 Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception 2010; 82 (02) 174-177
• 14 Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care 2016; 42 (03) 171-176
• 15 Lawrie TA, Hofmeyr GJ, De Jager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol 1998; 105 (10) 1082-1090
• 16 Stevens-Simon C, Kelly L, Wallis J. The timing of Norplant insertion and postpartum depression in teenagers. J Adolesc Health 2000; 26 (06) 408-413
• 17 Roberts TA, Hansen S. Association of hormonal contraception with depression in the postpartum period. Contraception 2017; 96 (06) 446-452